Somatotropin Penetration Testing from Formulations Applied Topically to the Skin

Growth hormone (somatotropin—STH) deficiency therapy requires daily injections of recombinant human growth hormone. The FDA approved treatment with STH one dose per week for the first time in 2021. However, injectable drug application is accompanied by numerous inconveniences. Therefore, an attempt was made to formulate a less invasive formulation topical skin. A substrate prepared based on polymer, methylcellulose (MC), into which introduced at concentration 1 mg/g. Simultaneously, formulations were STH, albumin (ALB) added different concentrations: 0.1%, 0.2% and 0.5%. test degree permeation carried out, as well effect ALB parameters. Selected rheological properties obtained investigated. simulated vivo conditions through porcine skin indicated relatively good bioavailability over 80% confirmed effectiveness MC carrier prolonged penetration rate increased 93%. hydrogels found be typical shear-thinning, thixotropic fluids.